Stockreport

Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutam...

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Retrospective study reinforces real-world efficacy of ERLEADA ® for patients with mCSPC HORSHAM, Pa. Feb. 2, 2026 /PRNewswire/ -- Johnson & Johnson today announced ne [Read more]